Simultaneous whole body ^(18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with ^(18)F-fluorodeoxyglucose positron emission tomography computed tomogra

作     者：Brian S Pugmire Alexander R Guimaraes Ruth Lim Alison M Friedmann Mary Huang David Ebb Howard Weinstein Onofrio A Catalano Umar Mahmood Ciprian Catana Michael S Gee 

作者机构：Department of Radiology Cincinnati Children’s Hospital Medical Center Division of Body Imaging Oregon Health Sciences University Division of Abdominal Imaging Massachusetts General Hospital Martinos Center for Biomedical Imaging Division of Nuclear Medicine and Molecular Imaging Massachusetts General Hospital Division of Pediatric Imaging Mass General Hospital for Children Division of Pediatric Hematology-Oncology Mass General Hospital for Children 

出 版 物：《World Journal of Radiology》 (世界放射学杂志（英文版）（电子版）)

年 卷 期：2016年第8卷第3期

页      面：322-330页

学科分类：1001[医学-基础医学(可授医学、理学学位)] 100106[医学-放射医学] 10[医学] 

主　　题：Positron emission tomography Radiology Pediatric imaging Oncology Cancer Magnetic resonance imaging 

摘      要：AIM: To describe our preliminary experience with simultaneous whole body ^(18)F-fluorodeoxyglucose(^(18)F-FDG)positron emission tomography and magnetic resonance imaging(PET-MRI) in the evaluation of pediatric oncology ***: This prospective, observational, singlecenter study was Health Insurance Portability and Accountability Act-compliant, and institutional review board approved. To be eligible, a patient was required to:(1) have a known or suspected cancer diagnosis;(2) be under the care of a pediatric hematologist/oncologist; and(3) be scheduled for clinically indicated ^(18)F-FDG PETCT examination at our institution. Patients underwent PET-CT followed by PET-MRI on the same day. PET-CT examinations were performed using standard department protocols. PET-MRI studies were acquired with an integrated 3 Tesla PET-MRI scanner using whole body T1 Dixon, T2 HASTE, EPI diffusion-weighted imaging(DWI) and STIR sequences. No additional radiotracer was given for the PET-MRI examination. Both PET-CT and PETMRI examinations were reviewed by consensus by two study personnel. Test performance characteristics of PETMRI, for the detection of malignant lesions, including FDG maximum standardized uptake value(SUVmax) and minimum apparent diffusion coefficient(ADCmin), were calculated on a per lesion basis using PET-CT as a reference ***: A total of 10 whole body PET-MRI exams were performed in 7 pediatric oncology patients. The mean patient age was 16.1 years(range 12-19 years) including 6 males and 1 female. A total of 20 malignant and 21 benign lesions were identified on PET-CT. PET-MRI SUVmax had excellent correlation with PET-CT SUVmax for both benign and malignant lesions(R = 0.93). PETMRI SUVmax 2.5 had 100% accuracy for discriminating benign from malignant lesions using PET-computed tomography(CT) reference. Whole body DWI was also evaluated: the mean ADCmin of malignant lesions(780.2 + 326.6) was significantly lower than that of benign lesions(1